



Amyotrophic lateral sclerosis caused by the *C9orf72* expansion in Norway – prevalence, ancestry, clinical and demographic variables

Cathrine Gøberg Olsen (1,2), Vette Nilsen Malmberg (3), Maria Fahlström (1), Karl Bjørnar Alstadhaug (4), Ingrid Kristine Bjørnå (5), Geir Julius Braathen (1), Geir Bråthen (6), Natasha Demic (7), Erika Hallerstig (8), Ineke HogenEsch (9), Morten Horn (10), Margitta T. Kampman (11), Grethe Kleveland (12) Unn Ljøstad (13,14), Angelina Maniaol (10), Åse Hagen Morsund (15), Ola Nakken (16), Katrin Schlüter (17), Stephan Schuler (18), Elin Seim (19), Heidi Øyen Flemmen (3) Ole-Bjørn Tysnes (20), Trygve Holmøy (2,16), Helle Høyer (1,2*)


1 Department of Neurology 1 Department of Medical Genetics, Telemark Hospital Trust, Skien, Norway. 2 Institute of Clinical Medicine, University of Oslo, Nordbyhagen, Norway. 3 Department of Neurology, Telemark Hospital Trust, Skien, Norway. 4 Department of Neurology, Nordland Hospital Trust, Bodø, Norway. 5 Department of Neurology, Vestre Viken Hospital Trust, Drammen, Norway. 6 Department of Neurology and Clinical Neurophysiology, St.Olavs Hospital, Trondheim University Hospital, Trondheim, Norway. 7 Department of Neurology, Vestfold Hospital Trust, Tønsberg, Norway. 8 Department of Neurology, Østfold Hospital Trust, Grålum, Norway. 9 Department of Neurology, Fonna Hospital Trust, Haugesund, Norway. 10 Department of Neurology, Oslo University Hospital, Oslo, Norway. 11 Department of Neurology, University Hospital of North Norway, Tromsø, Norway. 12 Department of Neurology, Innlandet Hospital Trust, Lillehammer, Norway. 13 Department of Neurology, Sørlandet Hospital Trust, Kristiansand, Norway. 14 Department of Clinical Medicine, University of Bergen, Norway. 15 Department of Neurology, Møre og Romsdal Hospital Trust, Molde, Norway. 16 Department of Neurology, Akershus University Hospital, Lørenskog, Norway. 17 Department of Neurology, Stavanger University Hospital, Stavanger, Norway. 18 Department of Neurology, Nord-Trøndelag Hospital Trust, Namsos, Norway. 19 Department of Neurology, Førde Hospital Trust, Førde, Norway. 20 Department of Neurology, Haukeland University Hospital, Bergen, Norway. * - Presenting author

Introduction


- ✓ Expansion of *C9orf72* is the most common genetic cause of amyotrophic lateral sclerosis (ALS).
- ✓ The *C9orf72* expansion cause ALS, frontotemporal dementia (FTD) or a combination of ALS and FTD.
- ✓ The *C9orf72* expansion has high incidence in Norway's neighboring countries Sweden and Finland.

AIM OF THE STUDY:



- 1) Determine the prevalence, geographic distribution and ancestry of *C9orf72*-positive ALS patients in Norway.
- 2) Identify differences between *C9orf72*-positive and *C9orf72*-negative ALS patients with regard to clinical presentation, family history and sociodemographic variables.



Methods



Results: Prevalence, regional differences and ethnicity



Genetic ethnicity of the included *C9orf72* positive ALS patients detected by PCA on NGS data. 43 out of 44 C9pos patients were of non-Finnish European descent. One patient had ~50% Finnish ancestry, and another had a partly South Asian ancestry. No African, American, East Asian, or Ashkenazi Jewish ancestry was detected.

Presenting author:

Helle Høyer, PhD
Clinical laboratory geneticist / Researcher
Department of Medical Genetics, Telemark Hospital
Division of Medicine and Laboratory Sciences, University of Oslo
Norway
helle.hoyer@stfh.no | +47 35 00 31 46



The authors declare no conflicts of interest

Results: Comparison of *C9orf72* positive and negative patients

Clinical characteristics		C9 _{pos} 8.8% (n=44)	C9 _{neg} 91.2% (n=456)	p Value
	Sex male, % (n)	52.3% (23)	58.8% (268)	0.404
	Age at onset, median years (IQR)	63 (54.3-69.0)	66 (57.0-72.0)	0.258
	Site of onset, % (n)			0.079
	Bulbar	28.6% (12)	26.0% (118)	
	Spinal	50.0% (21)	63.3% (286)	
	Both	21.4% (9)	10.6% (48)	
	Cognitive impairment (YES), % (n)	11.9% (5)	7.6% (34)	0.585
	Uncertain	2.4% (1)	3.3% (15)	
	Motor neuron sign, % (n)			0.322
	Upper domination	6.8% (3)	2.7% (12)	
	Lower domination	15.9% (7)	16.5% (73)	
	Both	77.3% (34)	80.8% (358)	
	Months from diagnosis until death	n=29	n=253	0.042
	Median (IQR)	16 (9.25-23)	19 (10-35)	

Family history		C9 _{pos} 8.8% (n=44)	C9 _{neg} 91.2% (n=456)	p Value
	Relatives with ALS, % (n)	50.0% (22)	11.0% (50)	<0.001
	1 st degree	34.1% (15)	6.8% (31)	
	2 nd degree	9.1% (4)	2.4% (11)	
	3 rd – 5 th degree	6.8% (3)	1.8% (8)	
	Relatives with neurodegen. dis. % (n)	50.0% (22)	31.6% (144)	0.011
	FTD	4.6% (2)	0.7% (3)	
	Alzheimer	6.8% (3)	2.0% (9)	
	Dementia unspecified	18.2% (8)	11.0% (50)	
	Parkinson	9.1% (4)	6.6% (30)	
	Unspecified/other	13.6% (6)	12.9% (59)	

Sociodemographic variables		C9 _{pos} 8.8% (n=44)	C9 _{neg} 91.2% (n=456)	p Value
	Relationship status, % (n)			<0.001
	Married/cohabitating	72.1% (31)	78.6% (352)	
	Unmarried/single	20.5% (9)	4.3% (19)	
	Widow/widower	4.5% (2)	8.1% (36)	
	Divorced	2.3% (1)	9.2% (41)	
	Number of children, % (n)			0.024
	None	23.3% (10)	9.1% (41)	
	One child	7.0% (3)	11.8% (53)	
	Two or more children	69.8% (30)	79.2% (357)	
	Education level, % (n)			0.641
	Primary school (≤ 10 years)	16.7% (7)	17.8% (80)	
	Secondary school (10-13 years)	42.9% (18)	35.6% (160)	
	Graduate school (≥ 14 years)	40.5% (17)	46.5% (209)	
	Centrality index, % (n)			0.996
	Urban (1 or 2)	40.9% (18)	40.8% (184)	
	Suburban (3 or 4)	43.2% (19)	42.8% (193)	
	Rural (5 or 6)	15.9% (7)	16.4% (74)	

Conclusion

- *C9orf72* is detected in 9% of Norwegian ALS patients with large regional differences.
- *C9orf72* patients are more likely to have a shorter disease duration, be unmarried, and have fewer children.
- Half of the *C9orf72* patients report no family history of ALS, highlighting the importance of considering genetic testing for all ALS patients.